We are live on ! Find out more
EIGR

Eiger BioPharmaceuticals, Inc.
EIGR

Delisted

EIGR was delisted on the 10th of April, 2024.

Back to rankings

2 hedge funds and large institutions have $1.85M invested in Eiger BioPharmaceuticals, Inc. in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

42% less capital invested

Capital invested by funds: $3.19M → $1.85M (-$1.34M)

92% less funds holding

Funds holding: 24 → 2 (-22)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 22

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
-22
Holders Change %
-91.67%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
22
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Ameriprise
Ameriprise
Minnesota
-$1.25M
2
SAM
Simplify Asset Management
Nevada
-$450K
3
AWP
Accretive Wealth Partners
New Jersey
-$170K
4
6CM
683 Capital Management
New York
-$148K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$141K
Name Holding Trade Value Shares
Change 		Change in
Stake
PBM
1
Propel Bio Management
California
$1.85M – – –
Osaic Holdings
2
Osaic Holdings
Arizona
$543 -$527 -288 -87%
Ameriprise
3
Ameriprise
Minnesota
– -$1.25M -250,178 Closed
SAM
4
Simplify Asset Management
Nevada
– -$450K -90,000 Closed
AWP
5
Accretive Wealth Partners
New Jersey
– -$170K -63,150 Closed
6CM
6
683 Capital Management
New York
– -$148K -29,660 Closed
Vanguard Group
7
Vanguard Group
Pennsylvania
– -$141K -28,201 Closed
BlackRock
8
BlackRock
New York
– -$95.6K -19,109 Closed
Geode Capital Management
9
Geode Capital Management
Massachusetts
– -$63.3K -12,652 Closed
Renaissance Technologies
10
Renaissance Technologies
New York
– -$56K -11,102 Closed
RC
11
RBF Capital
California
– -$54.9K -10,971 Closed
TRCT
12
Tower Research Capital (TRC)
New York
– -$9.75K -1,948 Closed
Bank of America
13
Bank of America
North Carolina
– -$5.88K -1,174 Closed
Acadian Asset Management
14
Acadian Asset Management
Massachusetts
– -$5K -1,064 Closed
Morgan Stanley
15
Morgan Stanley
New York
– -$1.83K -366 Closed
Royal Bank of Canada
16
Royal Bank of Canada
Ontario, Canada
– -$2K -362 Closed
BNP Paribas Financial Markets
17
BNP Paribas Financial Markets
France
– -$470 -94 Closed
National Bank of Canada
18
National Bank of Canada
Quebec, Canada
– -$93 -41 Closed
FDCDDQ
19
Federation des caisses Desjardins du Quebec
Quebec, Canada
– -$60 -12 Closed
TFA
20
Toth Financial Advisory
Virginia
– -$56 -11 Closed
Wells Fargo
21
Wells Fargo
California
– -$50 -10 Closed
UBS Group
22
UBS Group
Switzerland
– -$45 -9 Closed
JP Morgan Chase
23
JP Morgan Chase
New York
– -$25 -5 Closed
Citigroup
24
Citigroup
New York
– -$20 -4 Closed

EIGR Hedge Fund Activity: Q2 2024 in Review

2 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q2 2024, worth a combined $1.85M — down 42% from $3.19M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of EIGR and 0 opened new positions — a net loss of 22 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was Ameriprise, exiting entirely with an estimated $1.25M sold.

  • 2 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q2 2024, down from 24 in Q1 2024.
  • Funds reported $1.85M of Eiger BioPharmaceuticals, Inc. stock for Q2 2024, down 42% quarter-over-quarter.
  • 0 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q2 2024 and 22 closed out, a net change of -22 holders.
  • The largest Eiger BioPharmaceuticals, Inc. seller in Q2 2024 was Ameriprise, an estimated $1.25M sold.

Based on aggregated 13F filings for Q2 2024.